Glaukos Corp (GKOS)
140.83
-0.61
(-0.43%)
USD |
NYSE |
Nov 21, 16:00
140.78
-0.05
(-0.04%)
Pre-Market: 20:00
Glaukos Revenue (TTM): 360.35M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
September 30, 2024 | 360.35M |
June 30, 2024 | 341.72M |
March 31, 2024 | 326.43M |
December 31, 2023 | 314.71M |
September 30, 2023 | 303.57M |
June 30, 2023 | 296.79M |
March 31, 2023 | 289.08M |
December 31, 2022 | 282.86M |
September 30, 2022 | 284.88M |
June 30, 2022 | 288.32M |
March 31, 2022 | 293.72M |
December 31, 2021 | 294.01M |
September 30, 2021 | 294.00M |
June 30, 2021 | 284.13M |
March 31, 2021 | 237.59M |
December 31, 2020 | 224.96M |
September 30, 2020 | 217.57M |
June 30, 2020 | 211.25M |
March 31, 2020 | 238.29M |
December 31, 2019 | 236.98M |
Date | Value |
---|---|
September 30, 2019 | 225.21M |
June 30, 2019 | 210.61M |
March 31, 2019 | 195.17M |
December 31, 2018 | 181.28M |
September 30, 2018 | 168.85M |
June 30, 2018 | 165.36M |
March 31, 2018 | 163.48M |
December 31, 2017 | 159.25M |
September 30, 2017 | 150.78M |
June 30, 2017 | 139.94M |
March 31, 2017 | 127.21M |
December 31, 2016 | 114.40M |
September 30, 2016 | 101.50M |
June 30, 2016 | 90.93M |
March 31, 2016 | 80.13M |
December 31, 2015 | 71.70M |
September 30, 2015 | 65.54M |
June 30, 2015 | 58.66M |
March 31, 2015 | 52.00M |
December 31, 2014 | 45.59M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
211.25M
Minimum
Jun 2020
360.35M
Maximum
Sep 2024
281.06M
Average
288.70M
Median
Revenue (TTM) Benchmarks
Boston Scientific Corp | 15.91B |
Baxter International Inc | 17.28B |
Masimo Corp | 2.043B |
Teleflex Inc | 3.026B |
Perspective Therapeutics Inc | -- |